Beam Therapeutics Inc (NASDAQ: BEAM) on Monday, soared 22.29% from the previous trading day, before settling in for the closing price of $27.55. Within the past 52 weeks, BEAM’s price has moved between $13.52 and $35.25.
Annual sales at Healthcare sector company slipped by -20.88% over the past five years. The company achieved an average annual earnings per share of 5.49%. With a float of $91.50 million, this company’s outstanding shares have now reached $101.36 million.
Beam Therapeutics Inc (BEAM) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Beam Therapeutics Inc is 9.83%, while institutional ownership is 93.08%. The most recent insider transaction that took place on Dec 31 ’25, was worth 170,567. In this transaction Chief Financial Officer of this company sold 6,294 shares at a rate of $27.10, taking the stock ownership to the 73,706 shares. Before that another transaction happened on Dec 31 ’25, when Company’s Chief Legal Officer sold 1,254 for $27.10, making the entire transaction worth $33,983. This insider now owns 115,667 shares in total.
Beam Therapeutics Inc (BEAM) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.09 earnings per share (EPS) for the period topping the consensus outlook (set at -1.22) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.05% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Beam Therapeutics Inc (BEAM) is currently performing well based on its current performance indicators. A quick ratio of 6.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.43, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -4.65 in one year’s time.
